Holding(s) in Company

Tristel PLC

20 April 2026

 

Tristel plc

("Tristel" or the "Company")

Holding(s) in Company

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces that it was notified on 17 April 2026 that, as of 16 April 2026, Artemis Investment Management LLP, holds, 3.00216 per cent. of the Company's issued share capital.

For further information please contact:     

Tristel plc			Via Walbrook PR
Matt Sassone, Chief Executive Officer			www.investors.tristel.com
Anna Wasyl, Chief Financial Officer
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus / Lianne Applegarth / Anna Dunphy		Mob: [phone]
Cavendish Capital Markets Ltd			Tel: [phone]
Geoff Nash / Callum Davidson / Joe Smith (Corporate Finance)
Sunila de Silva (Corporate Broking) / Louise Talbot (Sales)

About Tristel plc

Tristel plc is a global infection prevention company focussed on the manufacture and supply of products using its unique proprietary chlorine dioxide (ClO2) chemistry. The Company is a market leader in manual decontamination of medical devices, supplying hospitals with products under the Tristel brand, which also encompasses its sporicidal surface disinfection range offered as a sustainable alternative to commonly used pre‑wetted plastic wipe.

Tristel's head office and manufacturing facility is located in Snailwell, near Cambridge, and operates globally employing approximately 270 people across 16 subsidiaries selling into 40+ countries. The Company targets delivering double-digit revenue growth annually, an adjusted EBITDA margin of at least 25% and a continuing progressive year-on-year growth in dividends, underpinned by robust cash generation. 

The Company has been listed on the London Stock Exchange's AIM market since 2005 (AIM: TSTL).

For more information about Tristel's product range please visit: https://tristel.com 

 

END